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ABSTRACT
Objectives: To systematically categorise cancer
research investment awarded to United Kingdom (UK)
institutions in the period 2000–2013 and to estimate
research investment relative to disease burden as
measured by mortality, disability-adjusted life years
(DALYs) and years lived with disability (YLDs).
Design: Systematic analysis of all open-access data.
Setting and participants: Public and philanthropic
funding to all UK cancer research institutions,
2000–2013.
Main outcome measures: Number and financial
value of cancer research investments reported in 2013
UK pounds (UK£). Mortality, DALYs and YLDs data
were acquired from the Global Burden of Disease
Study. A compound metric was adapted to estimate
research investment relative to disease burden as
measured by mortality, DALYs and YLDs.
Results: We identified 4299 funded studies with a
total research investment of £2.4 billion. The highest
fundings by anatomical sites were haematological,
breast, prostate, colorectal and ovarian cancers.
Relative to disease burden as determined by a
compound metric combining mortality, DALYs and
YLDs, gender-specific cancers were found to be
highest funded—the five sites that received the most
funding were prostate, ovarian, breast, mesothelioma
and testicular cancer; the least well-funded sites were
liver, thyroid, lung, upper gastrointestinal (GI) and
bladder. Preclinical science accounted for 66.2% of
award numbers and 62.2% of all funding. The top five
areas of primary research focus by funding were
pathogenesis, drug therapy, diagnostic, screening and
monitoring, women’s health and immunology. The
largest individual funder was the Medical Research
Council. In combination, the five lowest funded site-
specific cancers relative to disease burden account for
47.9%, 44.3% and 20.4% of worldwide cancer
mortality, DALYs and YLDs.
Conclusions: Research funding for cancer is not
allocated according to relative disease burden. These
findings are in line with earlier published studies.
Funding agencies and industry should openly
document their research investments to improve better
targeting of research investment.
INTRODUCTION
Cancers account for a high burden of mor-
bidity and mortality worldwide. The Global
Burden of Disease (GBD) Study estimates
that cancer of all types resulted in 8 235 700
deaths in 2013.1 Predominantly a disease of
older age, historically cancer prevalence was
high in high-income countries. However,
the majority of cancer burden has shifted to
low-income countries, which have experi-
enced economic growth with rapid demo-
graphic and epidemiological transitions. The
number of deaths from cancer are projected
to rise due to population growth and aging.2 3
Between 1990 and 2013, the proportion of all
deaths that was attributable to cancer rose
from 11.9% to 15.0%, largely among low-
income and middle-income countries and
Strengths and limitations of this study
▪ We systematically analyse UK investment in
cancer research and describe trends by cancer
site and type of science along the research
pipeline.
▪ We consider cancer research investments along-
side the global burden of disease to provide
pragmatic commentary about areas of UK
research strength and relative neglect to inform
funder strategy and contribute towards policy
discussions.
▪ Our study is dependent on the accuracy of ori-
ginal investment data from the funding bodies.
▪ We could not openly access date of private
sector research funding, nor were we able to
obtain disaggregated award data from Cancer
Research UK, which impedes analysis on the
equity and efficiency of investment decisions.
▪ Disease burden measures are typically an esti-
mate and are subject to the potential introduction
of bias; other variables influence funding deci-
sions beyond the burden of disease.
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site-speciﬁc cancers accounted for nine of the 50 leading
causes of death, worldwide.1
The socioeconomic impact of cancer, in terms of
direct costs involved in medical management as well as
indirect costs resulting from productivity loss, on
patients and caregivers are substantial. Direct
health-related costs of cancer have been estimated to
incur €51.0 billion within in the European Union4 and
$124.5 billion in the United States of America (USA).5
Indirect costs are estimated to account for additional
losses of €75.2 billion and $115.8 billion, respectively.
Economic evaluation of the impact of cancer outside of
these two geographical regions has been lacking.
Investment in research and development (R&D) for
cancers produces global public beneﬁts that have a posi-
tive effect locally and worldwide, irrespective of the site
of the work or the location of the institution receiving
an award, bringing substantial health, social and eco-
nomic beneﬁt.
There are several national and international funding
bodies that make cancer research investments along the
R&D pipeline, from preclinical studies through to clin-
ical trials and applied research. The United Kingdom
(UK) is one of the world’s leading investors and produ-
cers of global biomedical and health research. Previous
analyses by the Research Investments in Global Health
study (ResIn, http://www.researchinvestments.org) have
systematically analysed public and philanthropic awards
totalling £3.7 billion to UK institutions for infectious
disease from 1997 to 2013, and evaluated funding
against global disease burden6 7 and publications and
citations as a marker of research output.8 Tracking
investments in R&D provides information and evidence
to inform funding decisions and priority setting. Here,
we present a systematic analysis of cancer-related
research awarded by public and philanthropic funders
to UK institutions from 2000 to 2013, categorise the data
against a range of cancer-speciﬁc and cross-cutting
disease areas and assess the award data against global
measures of mortality, disability-adjusted life years
(DALYs) and years lived with disability (YLD) across
three time points and in the wider literature.
METHODS
Our methods build on those developed for the infec-
tious disease research investment analysis, which are
described in detail elsewhere6 7 and adapted in subse-
quent peer-reviewed publications (http://www.
researchinvestments.org/publications).
We systematically examined funding awards from a
number of public and philanthropic funding bodies
(including the Medical Research Council (MRC),
Department of Health, Biotechnology and Biological
Sciences Research Council, Engineering and Physical
Science Research Council, Wellcome Trust, European
Commission as well as nine members of the Association
of Medical Research Charities) between 2000 and 2013.
Information was obtained by downloading openly access-
ible information on the funder website, contacting the
funder to request the information or searching existing
funding databases. For each award, the title and abstract,
where available, were individually screened for relevance
to cancer research. We excluded awards that were (1)
not obviously or immediately relevant to oncology; (2)
led by a non-UK institution and (3) not considered to
be for R&D activity. Studies that were completed without
funding were also excluded. Private sector data were not
available to evaluate at the same level of detail as public
and philanthropic research award data, and were there-
fore excluded from this analysis.
Cancer Research UK (CRUK) would not provide their
funding data at individual award level and so could not
be included in the main analysis. There is some descrip-
tion of individual CRUK awards without grant amounts
available at https://europepmc.org/. We report total
number of studies in this analysis.
Where awards were described in currencies other than
UK pounds, these were converted to UK pounds using
the mean exchange rate in the year of the award. All
included awards were adjusted for inﬂation and
reported in 2013 UK pounds.
Each study in the data set was reviewed by one author
(either CDZ, GJG, MAE-H or MGH) and assigned to as
many of 14 cross-cutting categories as appropriate. The
14 association categories were paediatric, geriatric,
infection-associated, women’s health, men’s health,
occupational health, pathogenesis, diagnostic/screen-
ing/monitoring, drug therapy, radiotherapy, surgery,
immunology, psychosocial and global health. Awards
were deﬁned as global health if they were considered to
pursue a clear non-UK focus (eg, ‘thyroid cancer in
Kenya’). The other category was only used when none
of the aforementioned categories were deemed to be
appropriate. Studies were also allocated to one of ﬁve
categories along the R&D pipeline: preclinical; phase I,
II or III clinical trials; product development (including
phase IV activity); public health and cross-disciplinary
research. The cross-disciplinary category was deﬁned as
an award containing signiﬁcant components across two
distinct areas along the R&D pipeline (such as preclin-
ical research leading directly into a phase I trial).
Provisional datasets were circulated to all authors for
review and comment with checks by second authors on
sections of the data and any disagreements settled by
consensus. Final datasets were then again circulated for
further review by all authors. Microsoft Excel 2010 and
2013 and Stata (V13) softwares were used for data
analysis.
Global data on mortality, DALYs and YLDs were avail-
able at time points 2005, 2010 and 2013. All burden
data were sourced from the ﬁndings of the GBD study,
for 20131 9 10 and for 2010.11 12 Burden data from 2005
were obtained directly from colleagues at the Institute
for Health Metrics and Evaluation, USA. As deﬁned by
the GBD study, YLDs for a disease or injury are the sum
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of the YLDs for each sequela associated with the disease
or injury.10 DALYS are the sum of years of life lost
(YLLs) and YLDs for each age–sex–country group.9
In order to allow direct comparison of relative invest-
ment with global health metrics across disease areas and
between different time periods, metrics were adapted
from the infectious disease analyses to estimate the
‘investment per mortality/DALY/YLD observed7’. The
metrics were created using the following equation –
ðTotal research investment up to the year before
the time point=number of deaths, DALYs or YLD
at time pointÞ=number of years of investment included:
For example, for assessment of breast cancer mortality at
the 2013 time point, we took the sum of breast cancer
research investment 2000–2012 (£124 305 716) and
divided that by number of deaths reported in 2013
(471 000), and divided the result by the number of years
of investment included (13) to get an ‘investment per
mortality observed’ metric of £20.30.
These metrics were applied for research relating to 16
site-speciﬁc cancers, where there was comparable data in
the ResIn and GBD studies. We deﬁned lung cancer by
aggregating ‘tracheal, bronchus and lung cancer’
burden data from the GBD study. Similarly, we deﬁned
skin cancer by aggregating ‘malignant skin melanoma’
and ‘non-malignant skin cancer’, and we deﬁned upper
gastrointestinal (GI) cancer by aggregating ‘oesopha-
geal’ and ‘stomach cancer’. The use of total investment
and the division by number of years included aimed to
reduce the impact of the volatility of annual research
funding and the relatively short periods between time
points. Ranking scores of the investment metrics were
developed for the 16 sites of cancer against 2013
burdens. Cancers were ranked in order of relative invest-
ment against burden from high to low and assigned a
score (from 1 to 16). The mean ranking scores across
mortality, DALYs and YLDs were used to illustrate an
overall relative level of investment against 2013 global
disease burden.
Patient involvement
There was no patient involvement in this study.
RESULTS
We identiﬁed 4299 funded studies that met our inclu-
sion criteria (table 1). The funding for these studies
represented a total research investment of almost £2.4
billion. The mean award amount for each study was
£555 513 (SD £1 429 510) and median was £231 559
(IQR £114 619–487 063). A total of 2416 awards (56.2%
of total) were designated towards a named site-speciﬁc
cancer (table 1), equating to £1.0 billion (40.3% of
total). The top ﬁve cancer sites in terms of award
number were haematological, breast, colorectal, prostate
and skin; the bottom ﬁve were testicular, bone, bladder,
thyroid and cholangiocarcinoma (table 1). The top ﬁve
cancer sites in terms of total funding were haemato-
logical, breast, prostate, colorectal and ovarian; the
bottom ﬁve were testicular, mesothelioma, thyroid,
bladder and cholangiocarinoma. Mean funding per
award varied greatly between sites with prostate cancer
receiving the most (£1.47 million) and bladder cancer
the least (£117 385).
The top ﬁve areas of primary research focus, by
number of awards, were drug therapy, diagnostic, screen-
ing and monitoring, women’s health, immunology and
pathogenesis; the bottom ﬁve areas were men’s health,
surgery, occupational health, global health and geriatrics
(table 2). In terms of net funding, the top ﬁve areas of
research were pathogenesis, drug therapy, diagnostic,
screening and monitoring and women’s health and
immunology; the bottom ﬁve were surgery, psychosocial,
global health, occupational health and geriatrics.
The majority of awards were focused on preclinical
science, accounting for 66.2% of award numbers and
62.2% of all funding (table 3). In terms of award
number, this was followed by public health, cross-
disciplinary, phase I-III and product development. This
order was reﬂected in terms of net investment, although
cross-disciplinary studies ranked ahead of public health
studies. Phase I-III clinical trials received the highest
mean funding per award, at £736 172 (SD £3 361 312),
while public health research received the least, at
£496 744 (SD £1 000 757).
The largest individual funder of cancer research of
the studies identiﬁed was the MRC, accounting for
35.1% of all funding (table 4). The charitable sector was
responsible for 39.5% of all awards (excluding CRUK)
but 17.4% of funding. The European Commission was
responsible for the largest mean grant per award (£1.58
million).
We generated a compound ranking score for the 16
sites of cancer against 2013 global disease burdens,
across mortality, DALYs and YLDs (table 5). The amount
of investment per unit disease burden (£ per death/
DALY/YLD) was used to compile this compound
ranking score. The data for all site-speciﬁc cancers mea-
sured here are presented in the online supplementary
information (see online supplementary tables S1–S3 and
ﬁgures S1–S3). We identiﬁed the ﬁve sites that received
the most funding relative to disease burden as prostate,
ovarian, breast, mesothelioma and testicular cancer. The
least well-funded sites relative to disease burden were
cancers of the liver, thyroid, lung, upper GI and bladder.
We were able to obtain some disaggregated data for
3284 CRUK research grants during the period of interest
but this excluded individual award data. Compared with
the aggregation of all other funders, CRUK placed more
of a focus on funding towards cancers of the prostate,
ovary and liver—by study number these sites accounted
for 6.9%, 3.4% and 2.7% of CRUK-funded studies com-
pared with 2.1, 1.1 and 0.9% of all studies in our quanti-
tative database, respectively. CRUK preferentially funded
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Table 1 Cancer research investment awards and funding by site. All investment reported in 2013 UK pounds
All funders where investment data were available Cancer Research UK
Site of cancer
Number of
awards
Percentage
of total
Sum
investment (£)
Percentage
of total Mean award, £ (SD) Median award, £ (IQR)
Number of
awards
Percentage of
all oncology
research awards
Breast 571 13.3% £137 960 107 5.8% 241 611 (414 584) 135 752 (25 000–216 673) 273 8.3%
Haematological 1158 26.9% £381 008 394 16.0% 329 022 (476 943) 186 813 (120 437–272 324) 225 6.9%
Colorectal 147 3.4% £77 279 857 3.2% 525 713 (674 881) 251 800 (102 078–819 866) 205 6.2%
Prostate 92 2.1% £135 290 779 5.7% 1 470 552 (6 156 372) 333 757 (155 227–721 037) 123 3.7%
Ovarian 48 1.1% £44 709 938 1.9% 931 457 (3 380 145) 226 764 (131 990–627 401) 112 3.4%
Lung 82 1.9% £24 263 280 1.0% 295 893 (556 278) 146 123 (66 701–242 934) 89 2.7%
Skin 87 2.0% £22 179 011 0.9% 254 931 (453 726) 85 406 (69 629–248 603) 84 2.6%
Brain 22 0.5% £9 994 255 0.4% 454 284 (498 933) 401 046 (196 928–528 008) 83 2.5%
Upper GI 18 0.4% £19 094 230 0.8% 1 060 791 (1 448 010) 788 850 (80 964–1 296 962) 80 2.4%
Head and neck 20 0.5% £18 250 632 0.8% 912 531 (1 003 091) 389 751 (167 358–1 602 465) 68 2.1%
Renal 19 0.4% £13 885 496 0.6% 730 815 (678 732) 479 197 (244 075–1 252 574) 48 1.5%
Bladder 10 0.2% £1 173 856 0.0% 117 385 (106 902) 94 520 (29 264–173 855) 48 1.5%
Cervical 26 0.6% £14 328 402 0.6% 551 092 (877 250) 210 179 (88 934–368 402) 43 1.3%
Pancreatic 16 0.4% £9 453 577 0.4% 590 848 (519 850) 276 237 (191 804–1 033 948) 40 1.2%
Bone 13 0.3% £17 242 183 0.7% 1 326 322 (1 604 685) 685 853 (243 559–1 999 907) 29 0.9%
Liver 37 0.9% £25 037 541 1.0% 676 690 (847 151) 319 082 (177 974–776 480) 20 0.6%
Mesothelioma 30 0.7% £4 476 088 0.2% 149 202 (101 201) 137 103 (95 895–205 500) 11 0.3%
Cholangiocarcinoma 2 0.0% £582 405 0.0% n/a n/a 11 0.3%
Testicular 14 0.3% £5 949 990 0.2% 424 999 (507 277) 242 175 (102 938–411 010) 11 0.3%
Thyroid 4 0.1% £1 375 881 0.1% n/a n/a 7 0.2%
Total 4299 £2 388 152 318 555 513 (1 429 510) 231 559 (114 619–487 063) 3284
GI, gastrointestinal; n/a, not applicable.
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Table 2 Cancer research investment awards and funding by cross-cutting theme
Cross-cutting
theme
All funders where investment data were available Cancer Research UK
Number of
awards
Percentage
of total
Sum
investment (£)
Percentage
of total Mean award, £ (SD) Median award, £ (IQR)
Number of
awards
Percentage
of all oncology
research awards
Pathogenesis
(mechanism)
227 5.3% £1 374 387 838 57.6% 543 881 (955 710) 248 573 (135 752–506 232) 1674 51.0%
Drug therapy 1104 25.7% £620 961 060 26.0% 562 464 (1 910 050) 202 342 (105 622–436 559) 935 28.5%
Diagnostic,
screening and
monitoring
681 15.8% £359 618 823 15.1% 528 074 (1 155 156) 205 728 (102 672–513 836) 404 12.3%
Women’s health 640 14.9% £199 534 693 8.4% 311 773 (1 041 520) 153 845 (56 515–227 202) 287 8.7%
Immunology
(biologics)
451 10.5% £194 086 617 8.1% 430 347 (760 955) 240 052 (125 669–466 250) 212 6.5%
Radiotherapy 112 2.6% £88 262 353 3.7% 788 056 (2 413 445) 243 333 (106 175–439 419) 209 6.4%
Psychosocial 117 2.7% £23 445 835 1.0% 200 391 (352 410) 87 463 (27 317–239 059) 122 3.7%
Men’s health 111 2.6% £143 392 908 6.0% 1 291 828 (5 617 919) 285 203 (126 037–700 353) 120 3.7%
Paediatrics 175 4.1% £62 641 938 2.6% 357 953 (547 484) 183 099 (89 522–322 261) 118 3.6%
Surgery 72 1.7% £37 900 334 1.6% 526 393 (684 908) 235 413 (97 890–761 651) 95 2.9%
Infection associated 129 3.0% £56 819 379 2.4% 440 460 (798 013) 231 836 (134 693–439 378) 48 1.5%
Global health 12 0.3% £6 434 960 0.3% 536 246 (1 089 118) 129 738 (77 519–459 274) 12 0.4%
Geriatrics 7 0.2% £1 616 394 0.1% 230 913 (254 925) 121 623 (76 421–262 167) 8 0.2%
Occupational health 18 0.4% £2 576 841 0.1% 143 157 (116 928) 137 103 (33 857–199 998) 8 0.2%
Total 4299 £2 388 152 318 555 513 (1 429 510) 231 559 (114 619–487 063) 3284
All investment reported in 2013 UK pounds.
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Table 3 Cancer research investment awards and funding by type of science
Type of science
All funders where investment data were available Cancer Research UK
Number of
awards
Percentage
of total
Sum
investment (£)
Percentage
of total Mean award, £ (SD) Median award, £ (IQR)
Number of
awards
Percentage of
all oncology
research awards
Preclinical 2845 66.2% £1 485 997 379 62.2% 522 318 (1 006 600) 240 974 (132 188–490 872) 1809 55.1%
Phase I-III 303 7.0% £223 060 276 9.3% 736 172 (3 361 312) 178 535 (70 934–502 399) 647 19.7%
Product development 172 4.0% £104 214 364 4.4% 605 897 (2 213 394) 193 051 (75 270–360 813) 52 1.6%
Cross-disciplinary 441 10.3% £315 145 351 13.2% 714 615 (1 586 882) 238 523 (126 589–703 764) 328 10.0%
Public health 512 11.9% £254 333 282 10.6% 496 744 (1 000 757) 209 364 (82 870–383 623) 443 13.5%
Unable to specify 26 0.6% £5 401 666 0.2% n/a n/a 5 0.2%
Total 4299 £2 388 152 318 555 513 (1 429 510) 231 559 (114 619–487 063) 3284
All investment reported in 2013 UK pounds.
Table 4 Cancer research investment awards and funding by funding agency (excluding CRUK)
Funder
All funders where investment data were available
Number of
awards
Percentage
of total Sum investment (£)
Percentage
of total Mean award, £ (SD) Median award, £ (IQR)
MRC 768 17.9% £837 649 875 35.1% 1 090 690 (1 770 533) 504 606 (305 375–1 153 374)
Charity (excluding Wellcome and CRUK) 1699 39.5% £415 189 093 17.4% 244 372 (391 813) 151 912 (81 000–223 244)
Department of Health 586 13.6% £413 421 823 17.3% 705 498 (2 675 223) 232 173 (102 391–471 236)
BBSRC 511 11.9% £223 651 002 9.4% 437 673 (388 793) 373 356 (267 848–501 592)
EPSRC 356 8.3% £201 861 623 8.5% 567 027 (972 696) 306 906 (144 056–604 016)
Wellcome 193 4.5% £140 425 805 5.9% 727 594 (1 679 370) 226 761 (164 547–427 455)
European Commission (ERC) 50 1.2% £78 757 447 3.3% 1 575 149 (731 858) 1 409 678 (1 252 574–1 830 017)
Other 136 3.2% £77 195 650 3.2% 567 615 (1 901 202) 129 944 (69 309–263 613)
Total 4299 £2 388 152 318 555 513 (1 429 510) 231 559 (114 619–487 063)
All investment reported in 2013 UK pounds.
BBSRC, Biotechnology and Biological Sciences Research Council; CRUK, Cancer Research UK; EPSRC, Engineering and Physical Science Research Council; ERC, European Research
Council; MRC, Medical Research Council.
6
M
aruthappu
M
,etal.BM
J
Open
2017;7:e013936.doi:10.1136/bm
jopen-2016-013936
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 June 21, 2017 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
research investigating pathogenesis, which accounted for
51.0% of all grants awarded. In comparison, only 5.3%
of all awards in our quantitative database were identiﬁed
as primarily focused on pathogenesis.
DISCUSSION
We identiﬁed 4299 funded studies, with a total research
investment of £2.4 billion. We performed qualitative ana-
lysis on a further 3284 CRUK-funded awards. The vast
majority of all awards awarded were investigating at least
one of pathogenesis, diagnosis, monitoring and screen-
ing and drug therapy. In the absence of CRUK data, the
MRC and the Department of Health were the two
leading funding sources. Preclinical research accounted
for £1.5 billion (62.2%) of total R&D investment. Four
of the ﬁve highest funded cancer sites relative to global
disease burden were gender speciﬁc—namely prostate,
ovarian, breast and testicular cancers. Cancer research
with a clear focus on women’s health accounted for 640
studies (14.9%) and £199.5 million (8.4%) of invest-
ment. In comparison, 111 studies (2.6%) and £143.3
million (6.0%) of investment had a clear link with men’s
health. This may reﬂect the successes of various institu-
tions and charities that have sought to increase aware-
ness of these sex-speciﬁc cancers. Breast cancer, the
most commonly diagnosed cancer in the UK and the
leading cause of cancer death in women, and prostate
cancer, the second most frequently diagnosed cancer
and the sixth leading cause of cancer death among
men, were found to be relatively well funded.1 2
We highlight several cancer sites where there might be
underinvestment, namely that of liver, thyroid, lung,
upper GI tract and bladder. In our analysis, cancer of
the upper GI tract combines oesophageal and stomach
cancer. These site-speciﬁc cancers identiﬁed to be rela-
tively underfunded account for a substantial proportion
of global cancer burden. Globally, these sites account
for 47.9, 44.3 and 20.4% of the global mortality,1 DALYs9
and YLDs10 of all cancers, respectively. The disparity
between YLDs and DALYs demonstrates the poor prog-
nosis and high mortality of these particular sites when
compared against all neoplastic diseases. Lung, liver,
stomach and oesophagus are the ﬁrst, second, third and
ﬁfth, leading sites of neoplastic mortality worldwide.1
Two previous studies have compared UK cancer
funding with YLLs. Burnet et al13 reported the relative
overfunding of breast cancers and leukaemia. Carter
et al14 15 likewise reported higher levels of funding than
their burden suggests of testicular, leukaemia, Hodgkin’s
lymphoma, breast, cervical, ovarian and prostate cancer
with relative underfunding of gallbladder, lung, naso-
pharyngeal, intestine, stomach, pancreatic, thyroid,
oesophageal, liver, kidney, bladder and brain/central
nervous system (CNS). Furthermore, they show that
these broad discrepancies between cancer burden and
research investment are also reﬂected in the data from
the USA. Over the past decade in the UK, there has gen-
erally been a transition of increased funding towards
previously underfunded cancers with one notable excep-
tion being breast cancer. Although our site-speciﬁc clas-
siﬁcations differed slightly, our ﬁndings are broadly
consistent with these previous studies with the identiﬁca-
tion of haematological and sex-speciﬁc cancers being
relatively well funded. We are unable to account exactly
for the slight differences in our ﬁndings (such as cer-
vical and colorectal cancers); however, they are likely
due to our metrics which seek to capture mortality
Table 5 Compound ranking score for cancer research investment against 2013 global disease burdens, across
mortality, years lived with disability (YLDs) and disability-adjusted life years (DALYs), by cancer site
Disease
Research investment (UK pound) by burden observed, 2013
Mean ranking across
all burden metrics Mortality
Years lived with
disability
Disability-adjusted
life years
Prostate 2.7 2 4 2
Ovarian 3.0 4 2 3
Mesothelioma 4.0 6 1 5
Breast 4.0 3 5 4
Testicular 4.7 1 3 10
Skin 5.0 5 9 1
Colorectal 6.7 7 7 6
Renal 8.3 8 10 7
Cervical 9.7 9 12 8
Pancreatic 10.0 12 6 12
Brain 11.0 11 11 11
Thyroid 11.3 10 15 9
Liver 11.3 13 8 13
Lung 13.7 14 13 14
Upper GI 14.7 15 14 15
Bladder 16.0 16 16 16
GI, gastrointestinal
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(global mortality and DALYs) and life burden (DALYs
and YLDs) rather than just mortality, and also different
included components in the respective datasets.
With regard to interventions research, there is heavy
investment in drug-based modalities. A total of £620.9
million (26.0%) was invested in novel drug therapies and
£194.1 million (8.1%) was invested in the emergent role
of immunomodulation. In comparison, funding towards
radiotherapy and surgical interventions accounted for
£88.2 million (3.7%) and £37.9 million (1.6%), respect-
ively. In high-income settings, around half of new cancer
diagnoses will undergo a course of radiotherapy treat-
ment during their clinical management; roughly, a
quarter will receive two or more courses.16 17 Globally,
over 80% of cancer cases will warrant surgical interven-
tion, where it has preventative, diagnostic, curative, sup-
portive, palliative and reconstructive roles.18
Analysis by R&D pipeline showed that research invest-
ment in the UK places a heavy emphasis on preclinical
research, but relatively little investment towards phase
I-III clinical trials or product development, and this is in
line with previous research in infectious disease invest-
ment.6 This may reﬂect the strengths of UK institutions
in preclinical science, and could suggest a need to
strengthen research capacity further down the R&D
chain. It would be useful to determine whether invest-
ment reﬂects the priorities of funding agencies and
whether this is comparable with research investment in
other countries. We noted a lack of readily available data
from the pharmaceutical industry and this is likely to
leave a data gap in particular for sum totals of invest-
ment in clinical trials of pharmaceutical products.
Our ﬁndings contribute to the development of trans-
parent and objective methods to couple the allocation
of limited research funds with disease burden. Previous
studies have suggested that ﬁnancial investment might
appropriately be coupled with DALYs as a measure of
burden.19–22 Furthermore, previous UK research sug-
gests that publicly funded research offers substantial
rates of return in terms of health and monetary beneﬁt
in the case of cancer speciﬁcally23 and biomedical
sciences as a whole.25 We have further sought to incorp-
orate mortality rates and YLDs into the consideration of
cancer research investment. These analyses, when con-
sidered together, provide convincing pragmatic evidence
of UK research strength and types of cancer where
research investment has been particularly lacking.
We have chosen to compare cancer research funding
with global rather than domestic UK disease burden.
Owing to increasing globalisation, the emergence of
non-communicable disease burden in resource-poor set-
tings, the internationalisation of healthcare, the ﬂow of
people across national borders and the role of the UK
as an international centre of biomedical research, we
believe this approach to be justiﬁed.
However, deﬁning an appropriate amount of research
investment for each site-speciﬁc cancer is challenging
since cancers of similar disease burdens may warrant
different levels of investment to develop cost-effective
interventions. Decisions may be inﬂuenced by any of a
number of factors, for example, due to exceptional
need, as may be the case in mesothelioma, or due to
public awareness and third-party lobbying, as may be the
case with regards to the gender-speciﬁc cancers.
A variety of factors contribute towards the difﬁculty in
tracking net cancer research investment within the UK.
Fragmentation of data from a large number of diverse
public and private sources of funding, poorly designed
donor accounting structures and the paucity of disaggre-
gated information from the private sector limit the
quality of the evidence base and thus the ability to
inform policy in real time. In our study, we were unable
to obtain disaggregated investment data from CRUK,
despite requests across 2014 and 2015. It is noteworthy
however that CRUK representatives are welcoming and
encouraging the expansion of data-sharing and promot-
ing the availability, accessibility and discoverability of
such data 26, 27. In our experience across the ResIn
infection and cancer analysis, more than 200 high
proﬁle research funder in the UK and the USA have
been supportive of lending transparency to their invest-
ment proﬁles. The lack of data liberation across non-
communicable diseases impedes open scrutiny and
hinders timely and effective response to this growing
global disease burden.28 29 Transparency in the tracking
and monitoring of cancer research ﬁnancing is essential
to enable accountability and equity in resource alloca-
tion and to facilitate further future research in this area.
We would encourage CRUK to be more open in provid-
ing data on funding.
In this study, we systematically analyse UK investment
in cancer research and identify areas of relative neglect.
Although the competitive application process used by
most funders to allocate research grants ensure a port-
folio of high quality, the absence of explicit resource allo-
cation criteria could contribute towards inequalities in
R&D by disease burden. Funding agencies will have par-
ticular areas of focus, and UK funders may have consid-
ered the focus of international agencies in their own
research strategies. As a result, international data is essen-
tial to complete the mapping of cancer research invest-
ment. Nevertheless, our ﬁndings will inform funders and
contribute towards policy discussions that reduce inequi-
ties in the allocation of limited ﬁnancial resources.
By demonstrating the relationship between disease
burden and research funding, we enable the identiﬁca-
tion of potential investment gaps. However, it is not pos-
sible to fully equate gaps in funding with areas of neglect
without consideration of other inﬂuences such as the
feasibility of research, costs of technologies, infrastructure
and skill requirements, political and social considerations
and the accuracy of disease burden estimates.
There are several potential limitations to our study. We
are dependent on the accuracy of original investment
data as sourced from the funding bodies. Although
checks were made on any obvious discrepancies or
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errors, interpretation of these original data may contain
errors. We made no attempt to investigate the contribu-
tion of any indirect or estate costs. Currency conversions
were averaged across each ﬁnancial year and any intra-
year ﬂuctuations may not have been captured. Unless
clearly documented, we were unable to assess how
funding was distributed from lead institutions to collab-
orative partners. We considered individual awards, rather
than number of studies.
Furthermore, assignment of disease categories and
allocation of studies according to these categories is sub-
jective, and there might be disagreements regarding
certain inclusion criteria. As YLLs were not included in
our analysis, we may underrepresent the disease burden
of cancers that occur disproportionately in the young
and which are associated with poor survival, notably
cancers of the ovary, cervix and CNS.13 However, we
would expect any additional information offered by YLL
analysis to be predominantly captured by use of DALYs.
We could not openly access data of private sector
research funding, nor were we able to obtain disaggre-
gated award data from CRUK. While our analysis did
demonstrate that CRUK funding (with some exceptions)
broadly reﬂected the ﬁndings of our quantitative data-
base, it is likely that substantial awards towards particular
areas of research could skew results; for example, CRUK
are particularly keen to fund clinical trials, an area typic-
ally not covered to such an extent by other public and
philanthropic funders. In 2014/2015 CRUK invested
£394 million into research or research-related activity,
and we hypothesise that much of that would have met
our inclusion criteria for this analysis.30 Disease burden
measures are typically an estimate and are subject to the
potential introduction of bias from missing or unobtain-
able data as well as from differences in classiﬁcation and
diagnosis.
Our report presents the latest investment data on
cancer research awarded to UK institutions between
2000 and 2013. Cancers of the liver, thyroid, lung, upper
GI tract and bladder as well as research towards radio-
therapy and surgical techniques in particular may
warrant increased rates of investment. We will make the
entire database and associated ﬁgures available online
(http://www.researchinvestment.org) to assist policy-
makers, funding organisations and researchers in the
identiﬁcation of investment gaps. We further encourage
funding organisations to make their investment portfo-
lios openly accessible to facilitate future research.
We hope that open funding data in this area can con-
tribute to redressing the misalignments in investments
for cancer research. Cancer research can improve the
clinical course of disease and offer tangible improve-
ments in health outcomes.23 Access to open data across
all funders is essential, and transparency can assist policy-
makers and the scientiﬁc community in ensuring that
limited resources are allocated appropriately and thus
most effectively alleviate the extensive mortality and mor-
bidity associated with cancer.
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